Biological Psychiatry

Central Amygdala Discovery Efforts in Primates Reveals New Clues on Anxious Temperament.  88:e35-e36. 2020

Reciprocal Copy Number Variations at 22q11.2 Produce Distinct and Convergent Neurobehavioral Impairments Relevant for Schizophrenia and Autism Spectrum Disorder.  88:260-272. 2020

The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls.  88:169-184. 2020

The SETD6 Methyltransferase Plays an Essential Role in Hippocampus-Dependent Memory Formation.  87:577-587. 2020

Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene.  86:523-535. 2019

Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling 2019

AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.  84:591-600. 2018

Connective Tissue Growth Factor Is a Novel Prodepressant.  84:555-562. 2018

Volume of the Human Hippocampus and Clinical Response Following Electroconvulsive Therapy.  84:574-581. 2018

Reply to: It Is Time to Look for New Treatments for Posttraumatic Stress Disorder: Can Sympathetic System Modulation Be an Answer?.  84:e19-e20. 2018

Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis.  82:634-641. 2017

It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group.  82:e51-e59. 2017

Imaging biomarkers associated with cognitive decline: a review..  77:685-692. 2015

Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression.  77:256-265. 2015

Genome-wide studies of verbal declarative memory in nondemented older people: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium.  77:749-763. 2015

Meta-analysis of face processing event-related potentials in schizophrenia.  77:116-126. 2015

Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.  75:198-206. 2014

Sirtuin activity in dentate gyrus contributes to chronic stress-induced behavior and extracellular signal-regulated protein Kinases 1 and 2 cascade changes in the hippocampus.  74:927-935. 2013

Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons.  73:1024-1034. 2013

Inflammatory T helper 17 cells promote depression-like behavior in mice.  73:622-630. 2013

Magnetic transfer contrast accurately localizes substantia nigra confirmed by histology.  73:289-294. 2013

Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia.  71:906-914. 2012

Phasic nucleus accumbens dopamine encodes risk-based decision-making behavior.  71:199-205. 2012

Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia.  70:646-654. 2011

Cocaine cues drive opposing context-dependent shifts in reward processing and emotional state.  69:1067-1074. 2011

Novel approaches to the study of postmortem brain in psychiatric illness: Old limitations and new challenges.  69:127-133. 2011

Attention-deficit/hyperactivity phenotype in mice lacking the cyclin-dependent kinase 5 cofactor p35.  68:1163-1171. 2010

Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.  68:625-633. 2010

Phasic nucleus accumbens dopamine release encodes effort- and delay-related costs.  68:306-309. 2010

Modulation in Activation and Expression of Phosphatase and Tensin Homolog on Chromosome Ten, Akt1, and 3-Phosphoinositide-Dependent Kinase 1: Further Evidence Demonstrating Altered Phosphoinositide 3-Kinase Signaling in Postmortem Brain of Suicide Subjects.  67:1017-1025. 2010

Basolateral Amygdala Modulates Terminal Dopamine Release in the Nucleus Accumbens and Conditioned Responding.  67:737-744. 2010

Lasting Epigenetic Influence of Early-Life Adversity on the BDNF Gene.  65:760-769. 2009

Neurotrophin Receptor Activation and Expression in Human Postmortem Brain: Effect of Suicide.  65:319-328. 2009

Saliva Estriol Levels in Women with and Without Prenatal Antidepressant Treatment.  64:533-537. 2008

Altered Vesicular Glutamate Transporter Expression in the Anterior Cingulate Cortex in Schizophrenia.  63:766-775. 2008

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases.  62:1371-1379. 2007

Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents.  62:1217-1227. 2007

Tumor Necrosis Factor-α and Its Inducer Inhibit Morphine-Induced Rewarding Effects and Sensitization.  62:658-668. 2007

Inhibitory Control in High-Functioning Autism: Decreased Activation and Underconnectivity in Inhibition Networks.  62:198-206. 2007

Attention-Deficit/Hyperactivity Disorder and Comorbid Disruptive Behavior Disorders: Evidence of Pleiotropy and New Susceptibility Loci.  61:1329-1339. 2007

An Inducer for Glial Cell Line-Derived Neurotrophic Factor and Tumor Necrosis Factor-α Protects Against Methamphetamine-Induced Rewarding Effects and Sensitization.  61:890-901. 2007

Lithium Regulates Glycogen Synthase Kinase-3β in Human Peripheral Blood Mononuclear Cells: Implication in the Treatment of Bipolar Disorder.  61:216-222. 2007

Polymorphisms in the Regulatory Region of the Human Serotonin 5-HT2A Receptor Gene (HTR2A) Influence Gene Expression.  61:167-173. 2007

Schizophrenia-Relevant Behavioral Testing in Rodent Models: A Uniquely Human Disorder?.  59:1198-1207. 2006

Diffusion tensor imaging in schizophrenia.  58:921-929. 2005

Regarding “Antibiotic Prophylaxis with Azithromycin or Penicillin for Childhood-Onset Neuropsychiatric Disorders”.  58:917-917. 2005

Suicide brain is associated with decreased expression of neurotrophins.  58:315-324. 2005

Deep brain stimulation for refractory obsessive-compulsive disorder.  57:510-516. 2005

Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains.  57:252-260. 2005

Altered protein kinase A in brain of learned helpless rats: Effects of acute and repeated stress.  56:30-40. 2004

Effect of agonal and postmortem factors on gene expression profile: Quality control in microarray analyses of postmortem human brain.  55:346-352. 2004

Protein kinase a in postmortem brain of depressed suicide victims: Altered expression of specific regulatory and catalytic subunits.  55:234-243. 2004

Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus.  47:22-28. 2000

Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold.  45:1440-1446. 1999

D-fenfluramine challenge in posttraumatic stress disorder.  45:928-930. 1999

Protein kinase C in platelets of depressed patients.  44:909-911. 1998

Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins.  44:169-178. 1998

Antipsychotic properties of the partial dopamine agonist (-)-3-(3- hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia.  43:2-11. 1998

Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome.  42:781-796. 1997

Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression.  42:155-164. 1997

Effects of cocaine on D3 and D4 receptor expression in the human striatum.  38:263-266. 1995

Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia.  35:517-524. 1994

Effects of cocaine on dopamine receptor gene expression: A study in the postmortem human brain.  34:348-355. 1993

The effects of antidepressants on the thyroid axis in depression.  33:120-126. 1993

Expression of the dopamine D2 receptor gene in brain.  30:985-1007. 1991

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome.  29:953-964. 1991

Basal ganglia mineralization in schizophrenia.  29:296-297. 1991

Multiplicity of depressive episodes: Phenomenological and neuroendocrine correlates.  27:1156-1164. 1990

γ-melanotropin and β-endorphin after dexamethasone.  25:975-976. 1989

Positive and negative symptoms in schizophrenia and the dexamethasone suppression test.  25:788-792. 1989

Dexamethasone suppression test status and severity of depression.  24:693-696. 1988

Multiple depressive episodes and plasma postdexamethasone cortisol levels.  22:583-592. 1987

Postdexamethasone plasma cortisol and β-endorphin levels in depression: Relationship to severity of illness.  22:1137-1150. 1987

A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.  21:691-694. 1986

Quantification of muscle tremor of Huntington's disease patients and their offspring in an early detection study.  14:777-789. 1979

Diminution of early environmental control through perinatal and prenatal somatosensory deafferentation.  10:609-626. 1975